Headquartered in Quebec, an emerging biotechnology market, the company is a clinical stage cardiovascular drug development company developing novel small molecule therapeutics based on clinically validated mechanisms. Milestone’s lead product, MSP-2017, is a novel and potent short-acting calcium channel antagonist for the treatment of acute episodes of paroxysmal supraventricular tachycardia (PSVT) in an unmonitored setting. MSP-2017 is a derivative of verapamil, an approved drug for the target indication, but is expected to have a better safety profile.
Milestone is premised on this unmet medical need – currently there are no competing short-acting products for terminating acute PSVT episodes in an unmonitored setting.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.